drugset / Trial / NCT01827592

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

NCT01827592

Phase 3 Terminated 376 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.

Timeline

Start
2013-04
Primary completion
2014-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Elobixibat Small molecule 5 mg
Subject Elobixibat Small molecule 10 mg

Indications